Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2022

Login to access report north_east
Contact sales account_box

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate epidemiology, agitation affects the majority of patients diagnosed with AD and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck / Otsuka, Axsome Therapeutics, Avanir / Otsuka, and Intra-Cellular Therapies (among others) poised to enter the market beginning in 2023 and with blockbuster sales at stake, understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s off-label generic options will help identify levers for new product positioning and differentiation in this evolving market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do current off-label treatments perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European neurologists fielded in February 2022

Key companies: Otsuka / Lundbeck, Avanir / Otsuka, Axsome Therapeutics, Intra-Cellular Therapies 

Key drugs: Quetiapine, risperidone, olanzapine, aripiprazole, sertraline, lorazepam, gabapentin, Rexulti, AVP-786, AXS-05, ITI-1284 ODT-SL

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
north_east
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east